Compare Sea Limited (SE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Travere Therapeutics Inc. Common Stock — how do they compare? Sea Limited trades at $95 (market cap $58.76B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Sea Limited is far larger — about 12× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 103 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SE | TVTX | |
|---|---|---|
Market Cap | $58.76B | $4.88B |
Volume | 5,236,560 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $165.70 | $67.52 |
52-Week Low | $78.16 | $26.79 |
Typical Hold Time | 103 Days | 0 Days |
Enterprise Value | $53.78B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $95.31, down 0.59% with a bearish technical signal. The company shows strong revenue growth from $22.94B in 2025 to projected $27.7B in 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. Analyst consensus remains strongly bullish with 72.7% buy ratings and a $153.67 price target, representing 61% upside potential from current levels.
The investment case hinges on continued e-commerce and fintech growth despite recent stock weakness. Key risks include margin compression concerns and insider selling activity. Positive cash flow generation since 2025 and improving profitability metrics support the bullish analyst outlook, though technical indicators suggest near-term caution.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
